Symbols / SLNO Stock $52.75 +0.11% Soleno Therapeutics, Inc.
SLNO (Stock) Chart
About
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Stock Fundamentals
Scroll to Statements| Market Cap | 2.73B | Enterprise Value | 2.47B | Income | 20.48M | Sales | 190.40M | Book/sh | 8.61 | Cash/sh | 5.92 |
| Dividend Yield | — | Payout | 0.00% | Employees | 182 | IPO | — | P/E | 135.26 | Forward P/E | -23.24 |
| PEG | — | P/S | 14.33 | P/B | 6.13 | P/C | — | EV/EBITDA | 145.59 | EV/Sales | 12.97 |
| Quick Ratio | 5.44 | Current Ratio | 5.80 | Debt/Eq | 11.68 | LT Debt/Eq | — | EPS (ttm) | 0.39 | EPS next Y | -2.27 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-06 | ROA | 2.09% | ROE | 6.01% | ROIC | — |
| Gross Margin | 98.58% | Oper. Margin | 44.08% | Profit Margin | 10.97% | Shs Outstand | 51.72M | Shs Float | 47.90M | Short Float | 18.73% |
| Short Ratio | 5.10 | Short Interest | — | 52W High | 90.32 | 52W Low | 29.43 | Beta | -2.81 | Avg Volume | 3.39M |
| Volume | 1.23M | Target Price | $53.00 | Recom | Hold | Prev Close | $52.69 | Price | $52.75 | Change | 0.11% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-17 | down | Wells Fargo | Overweight → Equal-Weight | $53 |
| 2026-04-08 | down | HC Wainwright & Co. | Buy → Neutral | $53 |
| 2026-04-07 | down | TD Cowen | Buy → Hold | $53 |
| 2026-04-07 | down | Wolfe Research | Outperform → Peer Perform | — |
| 2026-04-06 | down | Cantor Fitzgerald | Overweight → Neutral | $53 |
| 2026-03-18 | main | Oppenheimer | Outperform → Outperform | $80 |
| 2026-03-04 | main | HC Wainwright & Co. | Buy → Buy | $100 |
| 2026-02-27 | main | Wells Fargo | Overweight → Overweight | $110 |
| 2026-02-26 | main | TD Cowen | Buy → Buy | $85 |
| 2026-01-20 | main | Wells Fargo | Overweight → Overweight | $114 |
| 2026-01-20 | main | HC Wainwright & Co. | Buy → Buy | $120 |
| 2025-11-18 | init | Wolfe Research | — → Outperform | $75 |
| 2025-11-05 | main | Wells Fargo | Overweight → Overweight | $106 |
| 2025-08-27 | reit | Guggenheim | Buy → Buy | $106 |
| 2025-08-20 | init | Wells Fargo | — → Overweight | $123 |
| 2025-08-18 | main | HC Wainwright & Co. | Buy → Buy | $110 |
| 2025-08-07 | main | Guggenheim | Buy → Buy | $106 |
| 2025-08-07 | main | Oppenheimer | Outperform → Outperform | $110 |
| 2025-07-11 | main | Baird | Outperform → Outperform | $121 |
| 2025-05-08 | main | Guggenheim | Buy → Buy | $97 |
- SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit - ChartMill Wed, 22 Apr 2026 22
- SLNO 13-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno - GlobeNewswire Wed, 22 Apr 2026 22
- Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Navigating the Biotech with a $2.73 Billion Market Cap and Promising Rare Disease Focus - DirectorsTalk Interviews Mon, 20 Apr 2026 09
- Soleno Therapeutics (SLNO) Still Appears Attractive Despite Slower U.S. Launch Ramp Projections - Yahoo Finance Wed, 01 Apr 2026 07
- Neurocrine Biosciences (NASDAQ: SLNO) offers $53.00 per share cash to Soleno - Stock Titan Mon, 20 Apr 2026 11
- Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Morningstar Wed, 22 Apr 2026 16
- Soleno Therapeutics (SLNO) Market Leadership | Q4 2025: EPS Beats Forecasts - Revenue Breakdown - Cổng thông tin điện tử tỉnh Lào Cai hu, 23 Apr 2026 04
- SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits Mon, 06 Apr 2026 07
- SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Hiding Post-Launch Safety Crisis: Levi & Korsinsky - ChartMill Wed, 22 Apr 2026 13
- Why Soleno Therapeutics Stock Rocketed Higher on Monday - Yahoo Finance Mon, 06 Apr 2026 07
- Are SLNO, BLD, STEL Obtaining Fair Deals for their Shareholders? - Morningstar Mon, 20 Apr 2026 20
- SLNO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - ChartMill Wed, 22 Apr 2026 12
- SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Hyperphagia Drug Launch Disruptions - Hagens Berman - ChartMill ue, 21 Apr 2026 21
- SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire ue, 21 Apr 2026 12
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNO - ChartMill ue, 21 Apr 2026 20
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
190.41
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
190.41
|
0.00
|
0.00
|
0.00
|
| Cost Of Revenue |
|
2.70
|
0.00
|
0.00
|
—
|
| Reconciled Cost Of Revenue |
|
2.70
|
0.00
|
0.00
|
—
|
| Gross Profit |
|
187.71
|
0.00
|
0.00
|
—
|
| Operating Expense |
|
172.75
-6.33%
|
184.43
+376.93%
|
38.67
+54.01%
|
25.11
|
| Research And Development |
|
40.63
-48.29%
|
78.57
+211.91%
|
25.19
+65.01%
|
15.27
|
| Selling General And Administration |
|
132.13
+24.81%
|
105.86
+685.26%
|
13.48
+36.95%
|
9.84
|
| General And Administrative Expense |
|
—
|
105.86
+685.26%
|
13.48
+36.95%
|
9.84
|
| Other Gand A |
|
—
|
105.86
+685.26%
|
13.48
+36.95%
|
9.84
|
| Total Expenses |
|
175.46
-4.87%
|
184.43
+376.93%
|
38.67
+54.01%
|
25.11
|
| Operating Income |
|
14.95
+108.11%
|
-184.43
-376.93%
|
-38.67
-54.01%
|
-25.11
|
| Total Operating Income As Reported |
|
9.41
+105.02%
|
-187.67
-353.49%
|
-41.38
-69.63%
|
-24.40
|
| EBITDA |
|
28.38
+116.35%
|
-173.63
-368.90%
|
-37.03
-67.53%
|
-22.10
|
| Normalized EBITDA |
|
33.92
+119.91%
|
-170.39
-399.18%
|
-34.13
-49.42%
|
-22.84
|
| Reconciled Depreciation |
|
2.02
+1.51%
|
1.99
+1.48%
|
1.96
-0.31%
|
1.96
|
| EBIT |
|
26.37
+115.01%
|
-175.62
-350.44%
|
-38.99
-62.00%
|
-24.07
|
| Total Unusual Items |
|
-5.54
-70.76%
|
-3.24
-11.95%
|
-2.90
-490.30%
|
0.74
|
| Total Unusual Items Excluding Goodwill |
|
-5.54
-70.76%
|
-3.24
-11.95%
|
-2.90
-490.30%
|
0.74
|
| Special Income Charges |
|
-5.54
-70.76%
|
-3.24
-19.45%
|
-2.71
-481.18%
|
0.71
|
| Restructuring And Mergern Acquisition |
|
5.54
+70.76%
|
3.24
+19.45%
|
2.71
+481.18%
|
-0.71
|
| Net Income |
|
20.89
+111.88%
|
-175.85
-351.04%
|
-38.99
-62.00%
|
-24.07
|
| Pretax Income |
|
20.89
+111.88%
|
-175.85
-351.04%
|
-38.99
-62.00%
|
-24.07
|
| Net Non Operating Interest Income Expense |
|
11.48
-2.92%
|
11.82
+358.53%
|
2.58
+759.33%
|
0.30
|
| Interest Expense Non Operating |
|
5.48
+2270.56%
|
0.23
|
0.00
|
0.00
|
| Net Interest Income |
|
11.48
-2.92%
|
11.82
+358.53%
|
2.58
+759.33%
|
0.30
|
| Interest Expense |
|
5.48
+2270.56%
|
0.23
|
0.00
|
0.00
|
| Interest Income Non Operating |
|
16.95
+40.66%
|
12.05
+367.49%
|
2.58
+759.33%
|
0.30
|
| Interest Income |
|
16.95
+40.66%
|
12.05
+367.49%
|
2.58
+759.33%
|
0.30
|
| Other Income Expense |
|
-5.54
-70.76%
|
-3.24
-11.95%
|
-2.90
-490.30%
|
0.74
|
| Gain On Sale Of Security |
|
—
|
—
|
-0.18
-706.67%
|
0.03
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
20.89
+111.88%
|
-175.85
-351.04%
|
-38.99
-62.00%
|
-24.07
|
| Net Income From Continuing Operation Net Minority Interest |
|
20.89
+111.88%
|
-175.85
-351.04%
|
-38.99
-62.00%
|
-24.07
|
| Net Income From Continuing And Discontinued Operation |
|
20.89
+111.88%
|
-175.85
-351.04%
|
-38.99
-62.00%
|
-24.07
|
| Net Income Continuous Operations |
|
20.89
+111.88%
|
-175.85
-351.04%
|
-38.99
-62.00%
|
-24.07
|
| Normalized Income |
|
26.43
+115.31%
|
-172.61
-378.24%
|
-36.09
-45.48%
|
-24.81
|
| Net Income Common Stockholders |
|
20.48
+111.64%
|
-175.85
-351.04%
|
-38.99
-62.00%
|
-24.07
|
| Otherunder Preferred Stock Dividend |
|
0.41
|
0.00
|
0.00
|
—
|
| Diluted EPS |
|
0.39
+108.90%
|
-4.38
-85.59%
|
-2.36
+17.77%
|
-2.87
|
| Basic EPS |
|
0.40
+109.13%
|
-4.38
-85.59%
|
-2.36
+17.77%
|
-2.87
|
| Basic Average Shares |
|
50.82
+26.49%
|
40.18
+143.61%
|
16.49
+96.40%
|
8.40
|
| Diluted Average Shares |
|
52.38
+30.39%
|
40.18
+143.61%
|
16.49
+96.40%
|
8.40
|
| Diluted NI Availto Com Stockholders |
|
20.48
+111.64%
|
-175.85
-351.04%
|
-38.99
-62.00%
|
-24.07
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
563.83
+70.36%
|
330.97
+83.17%
|
180.69
+581.93%
|
26.50
|
| Current Assets |
|
355.81
+21.07%
|
293.89
+71.51%
|
171.36
+995.15%
|
15.65
|
| Cash Cash Equivalents And Short Term Investments |
|
305.47
+4.82%
|
291.44
+71.76%
|
169.68
+1062.04%
|
14.60
|
| Cash And Cash Equivalents |
|
70.11
-20.27%
|
87.93
-48.18%
|
169.68
+1062.04%
|
14.60
|
| Other Short Term Investments |
|
235.37
+15.65%
|
203.51
|
0.00
|
—
|
| Receivables |
|
28.21
|
0.00
|
—
|
—
|
| Accounts Receivable |
|
28.21
|
0.00
|
—
|
—
|
| Inventory |
|
15.02
|
0.00
|
—
|
—
|
| Raw Materials |
|
6.45
|
0.00
|
—
|
—
|
| Work In Process |
|
2.71
|
0.00
|
—
|
—
|
| Finished Goods |
|
6.02
|
0.00
|
—
|
—
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
7.11
+189.97%
|
2.45
+46.21%
|
1.68
+60.48%
|
1.04
|
| Total Non Current Assets |
|
208.02
+460.95%
|
37.08
+297.33%
|
9.33
-13.98%
|
10.85
|
| Net PPE |
|
2.38
-20.38%
|
2.98
+612.17%
|
0.42
+166.88%
|
0.16
|
| Gross PPE |
|
2.50
-18.17%
|
3.05
+501.18%
|
0.51
+118.97%
|
0.23
|
| Accumulated Depreciation |
|
-0.12
-75.71%
|
-0.07
+21.35%
|
-0.09
-18.67%
|
-0.07
|
| Properties |
|
0.00
|
0.00
|
0.00
|
—
|
| Machinery Furniture Equipment |
|
0.21
+5.39%
|
0.20
+101.98%
|
0.10
+0.00%
|
0.10
|
| Other Properties |
|
2.19
-21.69%
|
2.80
+587.47%
|
0.41
+210.69%
|
0.13
|
| Leases |
|
0.09
+78.85%
|
0.05
|
0.00
|
—
|
| Goodwill And Other Intangible Assets |
|
4.86
-28.57%
|
6.80
-22.22%
|
8.75
-18.18%
|
10.69
|
| Other Intangible Assets |
|
4.86
-28.57%
|
6.80
-22.22%
|
8.75
-18.18%
|
10.69
|
| Investments And Advances |
|
200.62
+637.26%
|
27.21
|
0.00
|
—
|
| Other Non Current Assets |
|
0.16
+96.39%
|
0.08
-49.70%
|
0.17
|
—
|
| Total Liabilities Net Minority Interest |
|
113.72
+32.44%
|
85.86
+270.34%
|
23.18
+43.56%
|
16.15
|
| Current Liabilities |
|
61.36
+227.32%
|
18.75
+62.95%
|
11.51
+57.32%
|
7.31
|
| Payables And Accrued Expenses |
|
16.55
+23.09%
|
13.45
+105.52%
|
6.54
+30.87%
|
5.00
|
| Payables |
|
12.44
+40.00%
|
8.88
+182.06%
|
3.15
+77.21%
|
1.78
|
| Accounts Payable |
|
12.44
+40.00%
|
8.88
+182.06%
|
3.15
+77.21%
|
1.78
|
| Current Accrued Expenses |
|
4.11
-9.84%
|
4.56
+34.48%
|
3.39
+5.31%
|
3.22
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
9.68
+102.62%
|
4.78
+52.34%
|
3.13
+87.16%
|
1.68
|
| Current Debt And Capital Lease Obligation |
|
0.73
+38.02%
|
0.53
+92.67%
|
0.27
+76.13%
|
0.15
|
| Current Capital Lease Obligation |
|
0.73
+38.02%
|
0.53
+92.67%
|
0.27
+76.13%
|
0.15
|
| Other Current Liabilities |
|
20.38
+644.61%
|
2.74
+76.01%
|
1.55
+221.28%
|
0.48
|
| Total Non Current Liabilities Net Minority Interest |
|
52.35
-21.99%
|
67.11
+474.64%
|
11.68
+32.18%
|
8.84
|
| Long Term Debt And Capital Lease Obligation |
|
51.83
-0.90%
|
52.30
+40130.77%
|
0.13
|
0.00
|
| Long Term Debt |
|
49.86
+0.07%
|
49.83
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
1.96
-20.55%
|
2.47
+1801.54%
|
0.13
|
0.00
|
| Other Non Current Liabilities |
|
0.53
-96.46%
|
14.81
+28.25%
|
11.55
+30.72%
|
8.84
|
| Stockholders Equity |
|
450.12
+83.64%
|
245.11
+55.62%
|
157.51
+1422.10%
|
10.35
|
| Common Stock Equity |
|
450.12
+83.64%
|
245.11
+55.62%
|
157.51
+1422.10%
|
10.35
|
| Capital Stock |
|
0.05
+13.04%
|
0.05
+43.75%
|
0.03
+300.00%
|
0.01
|
| Common Stock |
|
0.05
+13.04%
|
0.05
+43.75%
|
0.03
+300.00%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
52.29
+14.40%
|
45.70
+44.28%
|
31.68
+288.24%
|
8.16
|
| Ordinary Shares Number |
|
52.29
+14.40%
|
45.70
+44.28%
|
31.68
+288.24%
|
8.16
|
| Additional Paid In Capital |
|
881.02
+26.41%
|
696.97
+60.63%
|
433.88
+75.12%
|
247.76
|
| Retained Earnings |
|
-431.37
+4.62%
|
-452.26
-63.62%
|
-276.41
-16.42%
|
-237.42
|
| Gains Losses Not Affecting Retained Earnings |
|
0.41
+14.96%
|
0.36
|
0.00
|
—
|
| Other Equity Adjustments |
|
0.41
+14.96%
|
0.36
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
450.12
+83.64%
|
245.11
+55.62%
|
157.51
+1422.10%
|
10.35
|
| Total Capitalization |
|
499.98
+69.52%
|
294.94
+87.26%
|
157.51
+1422.10%
|
10.35
|
| Working Capital |
|
294.45
+7.02%
|
275.14
+72.12%
|
159.85
+1818.08%
|
8.33
|
| Invested Capital |
|
499.98
+69.52%
|
294.94
+87.26%
|
157.51
+1422.10%
|
10.35
|
| Total Debt |
|
52.55
-0.52%
|
52.83
+13008.19%
|
0.40
+160.00%
|
0.15
|
| Capital Lease Obligations |
|
2.69
-10.27%
|
3.00
+643.92%
|
0.40
+160.00%
|
0.15
|
| Net Tangible Assets |
|
445.25
+86.84%
|
238.31
+60.20%
|
148.76
+43218.26%
|
-0.34
|
| Tangible Book Value |
|
445.25
+86.84%
|
238.31
+60.20%
|
148.76
+43218.26%
|
-0.34
|
| Available For Sale Securities |
|
200.62
+637.26%
|
27.21
|
—
|
—
|
| Current Provisions |
|
14.03
|
—
|
—
|
—
|
| Derivative Product Liabilities |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Interest Payable |
|
0.40
|
0.00
|
—
|
—
|
| Inventories Adjustments Allowances |
|
-0.16
|
0.00
|
—
|
—
|
| Investmentin Financial Assets |
|
200.62
+637.26%
|
27.21
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
46.80
+167.73%
|
-69.10
-177.05%
|
-24.94
-20.01%
|
-20.78
|
| Cash Flow From Continuing Operating Activities |
|
46.80
+167.73%
|
-69.10
-177.05%
|
-24.94
-20.01%
|
-20.78
|
| Net Income From Continuing Operations |
|
20.89
+111.88%
|
-175.85
-351.04%
|
-38.99
-62.00%
|
-24.07
|
| Depreciation Amortization Depletion |
|
2.02
+1.51%
|
1.99
+1.48%
|
1.96
-0.31%
|
1.96
|
| Depreciation And Amortization |
|
2.02
+1.51%
|
1.99
+1.48%
|
1.96
-0.31%
|
1.96
|
| Other Non Cash Items |
|
6.20
+68.07%
|
3.69
+21.45%
|
3.04
+819.19%
|
-0.42
|
| Stock Based Compensation |
|
45.85
-54.13%
|
99.96
+1581.38%
|
5.95
+134.98%
|
2.53
|
| Operating Gains Losses |
|
—
|
—
|
0.18
+706.67%
|
-0.03
|
| Gain Loss On Investment Securities |
|
—
|
—
|
0.18
+706.67%
|
-0.03
|
| Change In Working Capital |
|
-24.63
-509.32%
|
6.02
+105.53%
|
2.93
+487.30%
|
-0.76
|
| Change In Receivables |
|
-28.21
|
0.00
|
0.00
|
—
|
| Changes In Account Receivables |
|
-28.21
|
0.00
|
0.00
|
—
|
| Change In Inventory |
|
-14.03
|
0.00
|
0.00
|
—
|
| Change In Prepaid Assets |
|
-4.74
-531.73%
|
-0.75
+10.39%
|
-0.84
-840.71%
|
0.11
|
| Change In Payables And Accrued Expense |
|
8.51
+16.41%
|
7.31
+158.23%
|
2.83
+489.01%
|
-0.73
|
| Change In Accrued Expense |
|
4.90
+198.66%
|
1.64
+12.40%
|
1.46
+94.93%
|
0.75
|
| Change In Payable |
|
3.61
-36.32%
|
5.67
+313.41%
|
1.37
+192.89%
|
-1.48
|
| Change In Account Payable |
|
3.61
-36.32%
|
5.67
+313.41%
|
1.37
+192.89%
|
-1.48
|
| Change In Other Working Capital |
|
—
|
—
|
1.46
+54.17%
|
0.95
|
| Change In Other Current Liabilities |
|
13.83
+2637.80%
|
-0.55
-158.41%
|
0.93
+761.70%
|
-0.14
|
| Investing Cash Flow |
|
-201.78
+10.59%
|
-225.68
|
0.00
+100.00%
|
-0.01
|
| Cash Flow From Continuing Investing Activities |
|
-201.78
+10.59%
|
-225.68
|
0.00
+100.00%
|
-0.01
|
| Net PPE Purchase And Sale |
|
-0.07
+66.51%
|
-0.22
|
0.00
+100.00%
|
-0.01
|
| Purchase Of PPE |
|
-0.07
+66.51%
|
-0.22
|
0.00
+100.00%
|
-0.01
|
| Capital Expenditure |
|
-0.07
+66.51%
|
-0.22
|
—
|
-0.01
|
| Net Investment Purchase And Sale |
|
-201.71
+10.54%
|
-225.46
|
0.00
|
0.00
|
| Purchase Of Investment |
|
-455.78
-27.86%
|
-356.46
|
0.00
|
0.00
|
| Sale Of Investment |
|
254.07
+93.95%
|
131.00
|
0.00
|
0.00
|
| Financing Cash Flow |
|
137.16
-35.61%
|
213.03
+18.33%
|
180.02
+1177.46%
|
14.09
|
| Cash Flow From Continuing Financing Activities |
|
137.16
-35.61%
|
213.03
+18.33%
|
180.02
+1177.46%
|
14.09
|
| Net Issuance Payments Of Debt |
|
0.00
-100.00%
|
49.89
|
0.00
|
0.00
|
| Issuance Of Debt |
|
0.00
-100.00%
|
49.89
|
0.00
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
49.89
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
-100.00%
|
49.89
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
115.58
-22.41%
|
148.96
+8.05%
|
137.86
+877.15%
|
14.11
|
| Common Stock Payments |
|
-100.15
|
0.00
|
0.00
|
—
|
| Repurchase Of Capital Stock |
|
-100.15
|
0.00
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
22.39
+57.87%
|
14.18
-66.36%
|
42.16
|
0.00
|
| Net Other Financing Charges |
|
-0.80
|
—
|
—
|
-0.02
|
| Changes In Cash |
|
-17.82
+78.20%
|
-81.75
-152.72%
|
155.08
+2413.92%
|
-6.70
|
| Beginning Cash Position |
|
87.93
-48.18%
|
169.68
+1062.04%
|
14.60
-31.46%
|
21.30
|
| End Cash Position |
|
70.11
-20.27%
|
87.93
-48.18%
|
169.68
+1062.04%
|
14.60
|
| Free Cash Flow |
|
46.73
+167.41%
|
-69.31
-177.92%
|
-24.94
-19.94%
|
-20.79
|
| Interest Paid Supplemental Data |
|
4.53
+2069.38%
|
0.21
|
0.00
|
—
|
| Amortization Of Securities |
|
-3.52
+28.15%
|
-4.89
|
0.00
|
0.00
|
| Common Stock Issuance |
|
215.72
+44.82%
|
148.96
+8.05%
|
137.86
+877.15%
|
14.11
|
| Issuance Of Capital Stock |
|
215.72
+44.82%
|
148.96
+8.05%
|
137.86
+877.15%
|
14.11
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-07 View
- 8-K2026-04-06 View
- 42026-03-31 View
- 42026-03-31 View
- 8-K2026-03-16 View
- 42026-03-04 View
- 8-K2026-02-26 View
- 10-K2026-02-25 View
- 8-K2026-02-25 View
- 42026-01-23 View
- 42026-01-23 View
- 42026-01-23 View
- 42026-01-23 View
- 42026-01-23 View
- 42026-01-23 View
- 42026-01-23 View
- 42026-01-23 View
- 8-K2026-01-23 View
- 8-K2026-01-12 View
- 42025-12-17 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|